Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo (p=.095), as measured by the ADAS-Cog14 (Alzheimer's Disease Assessment Scale-Cognitive subscale).
While the study results, including many secondary clinical endpoints, directionally favored solanezumab, the magnitudes of treatment differences were small. There were no new safety signals identified in the study. Lilly will not pursue regulatory submissions for solanezumab for the treatment of mild dementia due to Alzheimer's disease.
"The results of the solanezumab EXPEDITION3 trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer's disease," said
Lilly will work with investigators to appropriately conclude the open-label extensions for EXPEDITION, EXPEDITION2 and EXPEDITION3. The next steps for the remaining elements of the solanezumab development program have not yet been determined.
"Lilly is grateful for the dedication of the patients, their families, and the clinical investigators who participated in this study," said
Lilly will present further findings from the study at the Clinical Trials on Alzheimer's Disease (CTAD) meeting on
"Lilly has strong growth prospects without solanezumab," said
The EXPEDITION3 study outcome is expected to result in a fourth-quarter charge of approximately
Solanezumab is Lilly's phase 3 monoclonal antibody being studied as a potential therapy for people with mild cognitive impairment due to Alzheimer's disease (EXPEDITION-PRO), preclinical Alzheimer's disease (Anti-Amyloid Treatment in Asymptomatic Alzheimer's "A4"), and Dominantly Inherited Alzheimer's Disease ("DIAN").
EXPEDITION3 is a multinational, phase 3 trial of solanezumab in more than 2,100 patients diagnosed with mild dementia due to Alzheimer's disease. The study includes an 18-month placebo-controlled period followed by an open label extension. Enrollment was completed in 2015 and the last patient visit for the placebo-controlled period occurred in
About Alzheimer's Disease
Alzheimer's disease is a fatal illness that is believed to start with changes in the brain that may begin 20 years or more before symptoms appear.1 Those changes cause a progressive decline in memory and other aspects of cognition that eventually lead to dementia.
Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases.1 There are currently an estimated 47 million people living with dementia worldwide.2 The number of people affected by dementia is expected to be nearly 75 million in 2030 and 131 million in 2050.2 Estimates vary, but experts suggest that as many as 5.4 million Americans may have Alzheimer's disease.1
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. P-LLY
This press release contains certain forward-looking statements about solanezumab, an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease, and the company's anticipated future results. These statements reflect Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. For further discussion of these and other risks and uncertainties and additional information about the factors that could cause actual results to differ materially from forward-looking statements, see Lilly's most recent Form 10-K and Form 10-Q filings with the
1 Alzheimer's Association. 2016 Alzheimer's Disease Facts and Figures. http://www.alz.org/documents_custom/2016-facts-and-figures.pdf. Accessed
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-announces-top-line-results-of-solanezumab-phase-3-clinical-trial-300367976.html
News Provided by Acquire Media